Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

NCT04577807 is registered in ClinicalTrials.gov with Istari Oncology, Inc. as lead sponsor.

NCT NCT04577807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04577807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Lead sponsor
Istari Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2020
Completion date
November 15, 2024
Enrollment
27 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma